Abstract: The primary objective of this project is to determine whether selenium supplementation affects candidate markers of breast cancer risk in a cohort of women at elevated risk for breast cancer. The intermediate biomarkers to be studied are: indicators of oxidative damage to cellular macromolecules such as DNA and lipid, indicators of IGF metabolic status, and cellular indicators of breast cancer risk. We propose a randomized, placebo-controlled, double-blind chemoprevention trial with 150 participants (75 subjects per arm) using a placebo tablet or a tablet containing 200 micro g high-selenium brewer's yeast per day, given for a duration of one year. The form and dose of selenium that will be used has been reported to reduce cancer incidence and mortality in lung, prostate, and colon. Blood and urine will be collected at baseline, and after 6 and 12 months of intervention. The feasibility of obtaining breast epithelial cells via nipple aspiration at baseline and the end of the intervention is being assessed. Plasma selenium and glutathione peroxidase activity will be evaluated in addition to pill counts and self report as markers of compliance.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 1 Aug 2003-31 Jul 2004 |
| Pages: |
6 |
| Report Date: |
AUG 2004 |
| Contract Number: |
DAMD17-01-1-0124 |
| Report Number: |
A275034 |
|
|
|
|
Keywords relating to this report:
